Home Newsfeeds JP Morgan Upgrades ServiceNow to Overweight

JP Morgan Upgrades ServiceNow to Overweight

JP Morgan analyst Mark Murphy upgrades ServiceNow (NYSE:NOW) from Neutral to Overweight.

byBenzinga Newsdesk

October 11, 2022

1 minute read

JP Morgan analyst Mark Murphy upgrades ServiceNow (NYSE:NOW) from Neutral to Overweight.

Analyst Ratings

Expert Ratings For Bicycle Therapeutics

By Benzinga Insights

April 10, 8:01 AM

During the last three months, 4 analysts shared their evaluations of Bicycle Therapeutics (NASDAQ:BCYC), revealing diverse outlooks from…

BCYC

Wells Fargo Initiates Coverage On Nutrien with Equal-Weight Rating, Announces Price Target of $80

By Benzinga Newsdesk

January 19, 5:57 AM

Wells Fargo analyst Richard Garchitorena initiates coverage on Nutrien (NYSE:NTR) with a Equal-Weight rating and announces Price Target of $80.

NTR

Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August

By Ragothaman Srinivasan

July 29, 4:36 PM

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ: ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older.

ARQT

ABVC BioPharma Provides Updates On ADHD Phase IIb Clinical Study; 60 Subjects Had Been Enrolled And 53 Had Completed The Eight-Week Study For The Co

By Happy Mohamed

August 23, 8:34 AM

ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced that 60 subjects had

ABVC

JP Morgan Upgrades ServiceNow to Overweight

Related Posts

Expert Ratings For Bicycle Therapeutics

Wells Fargo Initiates Coverage On Nutrien with Equal-Weight Rating, Announces Price Target of $80

Arcutis Gets FDA Nod For Plaque Psoriasis Candidate, Sees Commercial Launch In Mid-August

ABVC BioPharma Provides Updates On ADHD Phase IIb Clinical Study; 60 Subjects Had Been Enrolled And 53 Had Completed The Eight-Week Study For The Co